SIM
APLS

Spark Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History

Spark Investment Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-47,900
Closed -$1.15M – 543
2019
Q3 		$1.15M Buy
+47,900
New +$1.32M 0.15% 172
2019
Q1 		– Sell
-24,823
Closed -$327K – 640
2018
Q4 		$327K Buy
+24,823
New +$381K 0.02% 446

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Spark Investment Management's APLS Position: Q4 2019 in Review

Spark Investment Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2019, closing a stake of 47,900 shares — an estimated $1.15M sold.

Spark Investment Management first reported a position in APLS in Q4 2018 and held it in 2 quarters. The position peaked at $1.15M in Q3 2019. 133 funds tracked by Wall St. Rank hold APLS as of Q4 2019.

  • Spark Investment Management reported no remaining Apellis Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Spark Investment Management sold 47,900 Apellis Pharmaceuticals shares in Q4 2019, an estimated $1.15M.
  • Spark Investment Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Spark Investment Management's Apellis Pharmaceuticals position peaked at $1.15M in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2019.

Based on Spark Investment Management's 13F filing for Q4 2019, filed 11 Feb 2020.